TITLE: Methyl 2-Cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) Decreases Specificity Protein (Sp) Transcription Factors and Inhibits Pancreatic Tumor Growth

AUTHORS: Indira Jutooru, Gayathri Chadalapaka, Maen Abdelrahim, Md Riyaz Basha, Ismael Samudio, Marina Konopleva, Michael Andreeff, and Stephen Safe

JOURNAL: *Molecular Pharmacology* (MOL #64451)



Supplemental Figure 2. CDDO and CDDO-Me decrease transactivation of Sp1, Sp3, VEGF and survivin promoter constructs. Panc1 cells were treated with DMSO (solvent control), CDDO-Me (0.5, 1.0 or 1.25 μmol/L), or CDDO (2.5 or 5.0 μmol/L) and effects on transactivation of promoters were determined after treatment for 24 hr as described in Materials and Methods. Results are expressed as means ± SE for three replicate determinations for each treatment group, and significant ($P < 0.05$) decreases in luciferase activity compared to the solvent (DMSO) control are indicated (*).